Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors

Am J Hematol. 2022 May;97(5):E168-E171. doi: 10.1002/ajh.26483. Epub 2022 Feb 12.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide
  • Follow-Up Studies
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Prognosis
  • Rituximab
  • Treatment Outcome
  • Vidarabine / analogs & derivatives

Substances

  • Rituximab
  • Cyclophosphamide
  • Vidarabine
  • fludarabine